TIGIT, Human, 重组蛋白 (aa 22-141, His) TMPY-06462

Product Introduction
Bioactivity


英文名: TIGIT Protein, Human, Recombinant (aa 22-141, His)

描述: TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy

存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month

关键字: VSIG 9 | VSTM-3 | VSTM 3 | VSIG-9

TIGIT, Human, 重组蛋白 (aa 22-141, His) TMPY-06462信息由TargetMol中国为您提供，如您想了解更多关于TIGIT, Human, 重组蛋白 (aa 22-141, His) TMPY-06462报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途